Recombinant Human HLA-A*02:01&B2M&AFP(FMNKFIYEI) Tetramer Protein (HEK293)，Avi & His

The HLA-A*02:01/B2M/AFP (FMNKFIYEI) tetramer recombinant protein is significant in the field of immunology and cancer research, particularly in the context of hepatocellular carcinoma (HCC). Hepatitis B virus (HBV) infection and chronic liver disease are major risk factors for HCC, making the identification and targeting of tumor-associated antigens critical for developing effective immunotherapies. Alpha-fetoprotein (AFP) is a well-established biomarker for HCC, and the specific peptide FMNKFIYEI, presented by the HLA-A*02:01 molecule, is recognized by cytotoxic T lymphocytes (CTLs) in patients with HCC. The use of tetramers, which can bind to specific T cell receptors, allows for the accurate identification and isolation of AFP-specific CTLs, enhancing our understanding of T cell immunity against HCC. This recombinant protein serves as a valuable tool for studying T cell responses, evaluating the efficacy of vaccine candidates, and potentially guiding adoptive T cell therapies. Furthermore, it contributes to the broader aim of developing personalized immunotherapeutic approaches for HCC patients by identifying tumor-specific immune responses. As the incidence of HCC rises globally, research involving HLA-A*02:01/B2M/AFP tetramers holds promise for improving therapeutic strategies and patient outcomes in liver cancer treatments.